Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has increasingly been recognized not merely as a viral pneumonic illness but as a diffuse endothelial and microvascular disorder characterized by inflammation, thrombosis, vascular permeability, and dysregulated fluid homeostasis. Edema, traditionally viewed as a secondary manifestation of organ dysfunction, has emerged as a central pathophysiological feature across pulmonary, cardiovascular, renal, neurologic, dermatologic, and lymphatic manifestations of acute and post-acute COVID-19. The syndrome encompasses pulmonary edema associated with acute respiratory distress syndrome (ARDS), peripheral edema linked to endothelial injury and venous dysfunction, cerebral edema arising from neurovascular compromise, myocardial edema accompanying myocarditis, renal interstitial edema during acute kidney injury, and persistent tissue swelling in long COVID syndromes.

This review synthesizes current evidence regarding the relationship between COVID-19 and edema, emphasizing endothelial dysfunction, glycocalyx degradation, cytokine-mediated capillary leak, renin-angiotensin-aldosterone system dysregulation, coagulation abnormalities, and immune-mediated vascular injury. Clinical manifestations, epidemiology, diagnostic approaches, progression patterns, therapeutic strategies, and long-term outcomes are discussed in detail. Particular attention is devoted to the concept that SARS-CoV-2 induces a systemic vasculopathic state that disrupts hydrostatic and oncotic equilibrium across organ systems. Emerging evidence suggests that edema in COVID-19 is not simply a passive consequence of critical illness but an active manifestation of endothelial pathology and immune dysregulation.

The review further evaluates treatment approaches including corticosteroids, anticoagulation, endothelial-protective therapies, diuretics, ventilatory management, anti-inflammatory biologics, albumin replacement, and rehabilitation strategies for persistent edema syndromes. Finally, long-term vascular and lymphatic sequelae in post-acute sequelae of SARS-CoV-2 infection (PASC) are examined, including chronic venous insufficiency, dysautonomia-associated edema, microvascular inflammation, and persistent capillary dysfunction.

Introduction

The emergence of SARS-CoV-2 in late 2019 rapidly transformed the landscape of modern medicine. Initially characterized primarily as a viral respiratory infection, COVID-19 soon demonstrated systemic effects involving the vascular, renal, neurologic, cardiac, hematologic, and immune systems. Early reports from Wuhan, Italy, New York, and London described severe pulmonary edema and diffuse alveolar damage in critically ill patients. Subsequent histopathologic studies identified endothelialitis, capillary thrombosis, and widespread vascular inflammation as defining features of severe disease.

Edema constitutes one of the most clinically important manifestations of vascular injury in COVID-19. Although pulmonary edema associated with ARDS has long been recognized in viral pneumonias, SARS-CoV-2 appears uniquely associated with diffuse endothelial dysfunction and microvascular hyperpermeability. This observation has profound implications for understanding disease severity, progression, organ failure, and long-term morbidity.

The pathogenesis of edema in COVID-19 is multifactorial. Mechanisms include direct endothelial injury mediated by viral interaction with angiotensin-converting enzyme-2 (ACE2), cytokine-induced vascular leak, activation of complement pathways, glycocalyx degradation, dysregulation of the renin-angiotensin-aldosterone system (RAAS), coagulation abnormalities, cardiac dysfunction, renal impairment, lymphatic dysregulation, and prolonged inflammatory activation.

Accumulating evidence increasingly supports the hypothesis that COVID-19 represents a systemic endothelial disease rather than solely a pulmonary infection. Endothelial activation and dysfunction appear to contribute directly to vascular permeability, thrombosis, organ ischemia, and tissue edema. Histologic studies demonstrate diffuse endothelial inflammation, disruption of intercellular junctions, leukocyte infiltration, and microangiopathy in multiple organs.

The relationship between COVID-19 and edema has major clinical implications. Fluid accumulation contributes to respiratory failure, tissue hypoxia, impaired organ perfusion, neurologic injury, prolonged hospitalization, and mortality. Furthermore, persistent edema syndromes have emerged as a component of long COVID, suggesting chronic vascular and lymphatic abnormalities following acute infection.

This review critically examines the epidemiology, etiology, physiology, pathology, clinical characteristics, progression, treatment, and long-term consequences of edema associated with COVID-19. Emphasis is placed upon mechanistic understanding and translational implications for diagnosis and therapy.

Section I: Definitions and Physiologic Principles of Edema

Normal Fluid Homeostasis

Edema is defined as abnormal accumulation of fluid within the interstitial, intracellular, or serous compartments. Under physiologic conditions, fluid exchange between capillaries and tissues is tightly regulated by hydrostatic pressure, oncotic pressure, endothelial permeability, and lymphatic drainage.

Starling forces traditionally describe transvascular fluid movement:

Capillary hydrostatic pressure promotes fluid movement into tissues.
Plasma oncotic pressure, largely mediated by albumin, favors reabsorption into capillaries.
Endothelial permeability regulates protein and fluid escape.
Lymphatic drainage removes excess interstitial fluid.

The endothelial glycocalyx has emerged as a critical regulator of vascular permeability. This carbohydrate-rich layer lining the vascular endothelium maintains barrier integrity, prevents excessive protein leakage, and modulates leukocyte adhesion. Disruption of the glycocalyx promotes capillary leak and edema formation.

Mechanisms of Edema Formation

Edema generally develops through one or more mechanisms:

Increased capillary hydrostatic pressure
Reduced plasma oncotic pressure
Increased vascular permeability
Lymphatic obstruction or dysfunction
Sodium and water retention

COVID-19 may induce all five mechanisms simultaneously.

COVID-19 as a Disorder of Vascular Permeability

SARS-CoV-2 infection profoundly alters endothelial physiology. Viral interaction with ACE2 receptors initiates inflammatory signaling cascades that increase vascular permeability and disrupt endothelial junctional proteins. Cytokines including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and vascular endothelial growth factor (VEGF) further destabilize endothelial barriers.

These processes create a systemic capillary leak syndrome characterized by plasma extravasation, tissue swelling, impaired oxygen diffusion, and organ dysfunction.

Section II: Etiology of Edema in COVID-19

Viral-Endothelial Interaction

ACE2 receptors are highly expressed in endothelial cells throughout the pulmonary, cardiac, renal, intestinal, and cerebral vasculature. SARS-CoV-2 binding to ACE2 results in receptor internalization and dysregulation of RAAS signaling.

ACE2 ordinarily converts angiotensin II into angiotensin-(1-7), exerting vasodilatory, anti-inflammatory, and antifibrotic effects. Viral depletion of ACE2 leads to excessive angiotensin II activity, promoting:

Vasoconstriction
Oxidative stress
Endothelial inflammation
Increased vascular permeability
Sodium retention
Fibrosis

This imbalance contributes substantially to edema formation.

Histopathologic studies demonstrate endothelial swelling, apoptosis, and inflammatory infiltration in COVID-19. Endothelialitis has been documented in pulmonary, renal, cardiac, and intestinal tissues.

Cytokine Storm and Capillary Leak

Severe COVID-19 is associated with hyperinflammatory immune activation characterized by elevated cytokines including IL-1β, IL-6, interferon-γ, TNF-α, and granulocyte-macrophage colony-stimulating factor.

These mediators disrupt endothelial tight junctions and increase permeability through multiple pathways:

Activation of nuclear factor-kappa B (NF-κB)
Cytoskeletal contraction
Disruption of VE-cadherin
Oxidative endothelial injury
Leukocyte adhesion and transmigration

The resulting capillary leak syndrome resembles sepsis-associated vascular injury but appears particularly pronounced in COVID-19.

Glycocalyx Degradation

The endothelial glycocalyx is highly susceptible to inflammatory injury. COVID-19 induces glycocalyx shedding through oxidative stress, enzymatic degradation, and complement activation.

Loss of glycocalyx integrity causes:

Protein extravasation
Reduced oncotic containment
Enhanced leukocyte adhesion
Microvascular thrombosis
Tissue edema

Elevated circulating syndecan-1 levels in severe COVID-19 support extensive glycocalyx degradation.

Complement Activation

Complement-mediated endothelial injury contributes significantly to edema formation. Activation of C3a and C5a increases vascular permeability and promotes inflammatory recruitment.

Autopsy studies reveal complement deposition within pulmonary and dermal microvasculature. Complement-induced endothelial injury may contribute to diffuse alveolar edema and systemic capillary dysfunction.

Coagulopathy and Venous Congestion

COVID-19-associated coagulopathy includes microthrombosis, venous thromboembolism, and disseminated intravascular coagulation.

Venous obstruction increases hydrostatic pressure and contributes to localized edema, particularly in lower extremities and pulmonary circulation.

Deep vein thrombosis and pulmonary embolism may further exacerbate edema through impaired venous return and right ventricular dysfunction.

Cardiac Dysfunction

COVID-19-related myocarditis, stress cardiomyopathy, ischemia, and heart failure contribute to cardiogenic edema.

Mechanisms include:

Direct myocardial inflammation
Cytokine-mediated myocardial depression
Coronary microvascular thrombosis
Arrhythmias
Right ventricular strain secondary to pulmonary hypertension

Cardiac edema may manifest as pulmonary congestion, pleural effusions, peripheral edema, and ascites.

Renal Injury and Fluid Retention

Fluid retention and renal injury are tightly interwoven phenomena that reflect both the kidney’s central role in maintaining fluid homeostasis and its vulnerability to hemodynamic, inflammatory, and structural insults. When renal function declines—acutely or chronically—the body’s ability to regulate sodium and water balance becomes impaired, leading to edema, hypertension, and systemic congestion. Conversely, persistent fluid overload can itself worsen kidney injury through elevated venous pressures and reduced renal perfusion. This bidirectional relationship is now recognized as a key axis in disorders such as Acute Kidney Injury and Chronic Kidney Disease.

Physiology of Fluid Balance and Renal Regulation

The kidneys regulate extracellular fluid volume primarily through glomerular filtration, tubular reabsorption, and hormonal control systems including the renin–angiotensin–aldosterone system (RAAS), sympathetic nervous system, and antidiuretic hormone (ADH). Sodium handling is particularly important: water balance follows sodium balance, meaning that small shifts in renal sodium excretion can translate into large changes in total body fluid volume.

Under normal conditions, decreased effective circulating volume triggers sodium retention to preserve perfusion of vital organs. However, in renal injury states, this compensatory mechanism becomes maladaptive, leading to progressive fluid accumulation.

Mechanisms of Fluid Retention in Renal Injury

Fluid retention in kidney disease arises through several overlapping mechanisms:

1. Reduced Glomerular Filtration Rate (GFR)
When GFR declines, filtered sodium and water decrease, but tubular reabsorption mechanisms may remain active or become exaggerated, causing net retention.

2. RAAS Activation
Renal hypoperfusion—whether from true volume depletion or “perceived” low perfusion (as in heart failure or cirrhosis)—activates RAAS. Angiotensin II increases sodium reabsorption, while aldosterone promotes distal tubular sodium retention and potassium excretion.

3. Capillary Leak and Inflammation
In acute kidney injury, systemic inflammation can increase vascular permeability, shifting fluid from the intravascular to interstitial space, worsening edema even without large total body fluid gains.

4. Venous Congestion
Elevated central venous pressure impairs renal perfusion by increasing renal interstitial pressure. This mechanism is increasingly recognized in cardiorenal syndrome.

5. Hypoalbuminemia
In chronic kidney disease and nephrotic syndromes, loss of albumin reduces plasma oncotic pressure, allowing fluid to shift into interstitial spaces.

Pathophysiology of Renal Injury from Fluid Overload

While kidney injury promotes fluid retention, the reverse is also true: fluid overload contributes directly to worsening renal function.

Renal venous hypertension reduces the pressure gradient across the glomerulus, lowering filtration efficiency. Increased interstitial pressure compresses renal tubules and microvasculature, impairing oxygen delivery and waste removal.

Additionally, fluid overload can:

Reduce responsiveness to diuretics
Dilute plasma proteins and impair drug distribution
Promote systemic inflammation and endothelial dysfunction
Worsen hypertension, further damaging renal microvasculature

This feedback loop is especially evident in critically ill patients and those with decompensated heart failure.

Clinical Manifestations

Patients with combined fluid retention and renal injury may present with:

Peripheral edema (legs, sacrum, periorbital region)
Pulmonary edema leading to dyspnea and hypoxia
Rapid weight gain due to fluid accumulation
Hypertension, often resistant to treatment
Decreased urine output (oliguria) in acute settings
Fatigue and confusion in severe uremia

In advanced cases, fluid overload can progress to respiratory failure due to alveolar flooding.

Diagnostic Evaluation

Assessment requires integrating clinical, laboratory, and imaging findings:

Serum creatinine and estimated GFR: key markers of renal filtration
Urinalysis: proteinuria, hematuria, and casts may indicate intrinsic renal disease
Electrolytes: hyponatremia is common in dilutional states
BNP or NT-proBNP: helpful in distinguishing cardiac contributions
Ultrasound: evaluates kidney size, obstruction, and venous congestion
Physical exam: jugular venous distension, crackles, and edema grading

Treatment Strategies

Management focuses on breaking the cycle between renal dysfunction and fluid overload.

1. Diuretic Therapy
Loop diuretics (e.g., furosemide) are first-line agents to promote sodium and water excretion. In resistant cases, combination therapy with thiazides may enhance effect.

2. Fluid Restriction and Sodium Control
Dietary sodium restriction is essential to reduce ongoing fluid accumulation. Fluid restriction is used in hyponatremic or severely overloaded patients.

3. Renal Replacement Therapy
In severe Acute Kidney Injury with refractory fluid overload, dialysis may be necessary to remove excess fluid and metabolic waste.

4. Hemodynamic Optimization
Maintaining adequate renal perfusion pressure is critical. Overuse of vasoconstrictors or aggressive diuresis can worsen kidney injury.

5. Treating Underlying Causes
Management of sepsis, heart failure, nephrotoxic exposure, or autoimmune disease is essential for renal recovery.

Long-Term Consequences

Chronic fluid overload and persistent renal injury contribute to progressive cardiovascular and renal damage. Patients with Chronic Kidney Disease are at high risk for:

Left ventricular hypertrophy
Accelerated atherosclerosis
Pulmonary hypertension
End-stage renal disease requiring dialysis or transplantation

Even mild chronic congestion has been associated with increased mortality in heart–kidney interaction syndromes.

Conclusion

Fluid retention and renal injury exist in a self-reinforcing pathological cycle. Reduced kidney function promotes sodium and water retention, while excess fluid burden further impairs renal perfusion and accelerates damage. Understanding this bidirectional relationship is essential for effective treatment, particularly in conditions such as acute kidney injury, chronic kidney disease, and cardiorenal syndrome. Early recognition and intervention aimed at restoring fluid balance and preserving renal function remain central to improving outcomes.

Footnotes / References

Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from consensus conference. Eur Heart J. 2010.
Guyton AC, Hall JE. Textbook of Medical Physiology. Elsevier.
Hall JE. Renin-angiotensin system and renal control of sodium balance. Physiol Rev. 2016.
Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012.
Zarbock A, Gomez H, Kellum JA. Sepsis-induced AKI. Nat Rev Nephrol. 2014.
Mullens W, Abrahams Z, Skouri HN, et al. Elevated venous pressure and renal dysfunction. Circulation. 2009.
Daugirdas JT, Blake PG. Handbook of Dialysis. Wolters Kluwer.
Soni SS, Ronco C. Cardiorenal syndrome pathophysiology. Blood Purif. 2010.
Ellison DH. Diuretic resistance mechanisms. Clin J Am Soc Nephrol. 2011.
House AA, Anand I, Bellomo R, et al. Fluid overload and outcomes in AKI. Crit Care. 2013.
Beaubien-Souligny W, et al. Venous congestion by ultrasound. JACC. 2020.
Brater DC. Diuretic therapy. N Engl J Med. 1998.
KDIGO Clinical Practice Guideline for AKI. Kidney Int Suppl. 2012.
Damman K, Navis G, Smilde TD, et al. Congestion in heart failure and renal outcomes. Eur J Heart Fail. 2007.

COVID-19 and Edema